We are delighted to have started conducting clinical trials within Mayday University Hospital's flagship facilities. Construction and development of the new purpose built units was completed in May, allowing Early Phase studies to commence and complement our other premises within St George's University London.

“We moved into our new premises in early May and we are now conducting clinical research within the Mayday units. The transition has been very smooth and we are already reaping the rewards of the enhanced set-up.”— Dr Jörg Täubel, Managing Director, Richmond Pharmacology.
“Running clinical trials in our Mayday unit is proving very advantageous. The additional capacity we can manage up to 100 in-patients simultaneously. Our facilities are designed specifically for client and panel requirements and this helps trial conduct to run efficiently. For example, we now have dedicated monitoring facilities on the ward, with adjoining offices for a variety of support functions. I'm looking forward to taking full advantage of these facilities.”— Jean Van Wyk, Senior Research Physician and Head of Medical Department.
“The facilities have been purpose built, and this provides a tremendous advantage for our volunteers. The wards and recreational areas are spacious and comfortable. Volunteer feedback on the internet and lounge rooms has been very favourable. And, of course, it's reassuring to work within the acute environment of the NHS Trust.”— Dr Ulrike Lorch, Medical Director.

Latest news

Medicines Marketing UK / EU vs US: Why Your Launch Strategy Needs a Continental Divide - Dr Lisa Campbell, Director of Regulatory Strategy

September 12, 2025
A UK CRO’s perspective on planning clinical trials for global success For pharmaceutical companies preparing for global expansion, launching in both the US and EU / UK markets often seems like the natural next step. Yet success in one region does not guarantee success in the other.
Read more

Events

JSCPT 2025

5 – 6 December 2025
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
View event